Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $13.2 million.

  • Krystal Biotech's Share-based Compensation fell 122.41% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year increase of 1859.11%. This contributed to the annual value of $49.1 million for FY2024, which is 2302.36% up from last year.
  • Krystal Biotech's Share-based Compensation amounted to $13.2 million in Q3 2025, which was down 122.41% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Share-based Compensation registered a high of $14.1 million during Q2 2025, and its lowest value of $2.3 million during Q1 2021.
  • Over the past 5 years, Krystal Biotech's median Share-based Compensation value was $9.6 million (recorded in 2022), while the average stood at $9.4 million.
  • Per our database at Business Quant, Krystal Biotech's Share-based Compensation surged by 17799.39% in 2022 and then tumbled by 1090.35% in 2024.
  • Krystal Biotech's Share-based Compensation (Quarter) stood at $5.1 million in 2021, then surged by 85.66% to $9.6 million in 2022, then increased by 3.15% to $9.9 million in 2023, then surged by 35.55% to $13.4 million in 2024, then fell by 1.52% to $13.2 million in 2025.
  • Its Share-based Compensation stands at $13.2 million for Q3 2025, versus $14.1 million for Q2 2025 and $13.5 million for Q1 2025.